Mizuho on Apellis Pharmaceuticals (APLS): 'a Great Outcome'

April 15, 2026 10:28 AM

Mizuho analyst Graig Suvannavejh reiterated a Neutral rating and $41.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS)The analyst comments "Yesterday ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found